Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
About this item
Full title
Author / Creator
Rosenthal, A , Luthi, J , Belohlavek, M , Kortüm, K M , Mookadam, F , Mayo, A , Fonseca, R , Bergsagel, P L , Reeder, C B , Mikhael, J R and Stewart, A K
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore implemented a detailed, prospective, clinical cardiac and renal evaluation of 62 Cfz-treated myeloma patients, including serial blood pressure (BP), creatinine, troponin, NT-proBNP and pre- and post-t...
Alternative Titles
Full title
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4742629
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4742629
Other Identifiers
ISSN
2044-5385
E-ISSN
2044-5385
DOI
10.1038/bcj.2015.112
